ANN ARBOR, Mich. & TAIPEI, Taiwan--(BUSINESS WIRE)--BlueWillow Biologics, Inc., a pioneer in intranasal vaccine development, and Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, today announced that its intranasal COVID-19 booster (BW-1019) provided protection and boosted immune response when administered following an intramuscular vaccine series in preclinical studies.
AIPEI, 22 November 2021 - Medigen Vaccine Biologics nCorp (MVC) announced today that the company has been granted ProvisionalnDetermination for its COVID-19 vaccine candidate, MVC-COV1901 with the Therapeutic Goods Administration (TGA)nMedigen Vaccine Biologics Corp) in relation to its COVID-19 vaccine: nMVC-COV1901-S-2P-Protein (MVC-COV1901 Vaccine).
TAIPEI, Taiwan and EMERYVILLE, Calif., Aug. 23, 2021 /PRNewswire/ -- Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the rollout of its COVID-19 vaccine, MVC-COV1901. Approximately 600,000 people are anticipated to receive the Medigen vaccine this week.
Taiwan's Medigen Vaccine Biologics Corp said on Tuesday it will start a late-stage clinical trial this year in Paraguay for its COVID-19 vaccine, part of the island's push to make its own shots against the coronavirus.
TAIPEI (Reuters) -Taiwan's government on Monday approved the emergency use and production of Medigen Vaccine Biologics Corp's COVID-19 vaccine candidate, a major step in the island's plans to develop its own vaccines to protect against the coronavirus.
Medigen Vaccine Biologics Corporation (MVC), a biopharmaceutical company focusing on the development and production of vaccines and biologics based in Taiwan, and Dynavax Technologies Corporation, a US based biopharmaceutical company focused on developing and commercializing vaccines, have announced that the first participant has been dosed in the Phase 2 clinical trial evaluating MVC's COVID-19 vaccine candidate, MVC-COV1901.
Medigen Vaccine Biologics Corporation (MVC), a biopharmaceutical company focusing on the development and production of vaccines and biologics based in Taiwan, and Dynavax Technologies Corporation, a US based biopharmaceutical company focused on developing and commercializing vaccines, have announced that the first participant has been dosed in the Phase 2 clinical trial evaluating MVC's COVID-19 vaccine candidate, MVC-COV1901.
TAIPEI, TAIWAN and EMERYVILLE, Calif., Jan. 25, 2021 /PRNewswire/ -- Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO) a biopharmaceutical company focusing on the development and production of vaccines and biologics, and Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that the first participant has been dosed in the Phase 2 clinical trial evaluating MVC's COVID-19 vaccine candidate, MVC-COV1901. MVC-COV1901 is a subunit vaccine with recombinant S-2P antigen adjuvanted with CpG 1018 supplied by Dynavax.
Vaxess Technologies, an innovative biotechnology company in the US developing the MIMIX smart release patch, has formed a partnership with Taiwanese pharmaceutical company, Medigen Vaccine Biologics Corp. (MVC), to develop a combined COVID-19 and quadrivalent seasonal influenza vaccine (QIV), delivered via the novel MIMIX patch system.